Production Capacity Doubled for Prefillable Polymer Syringes

To address the increasing global demand for prefillable polymer syringes, Schott is currently expanding its manufacturing capacity for small size (1 to 10 ml) Schott TopPac® syringes. A new production line installed at the Schott site in St. Gallen, Switzerland, expanded the existing production capacity by 100% from April onwards. This enables Schott to offer customers a greater degree of flexibility and ensure supply security.

Schott is a pioneer in establishing the Schott TopPac® product range as ready-to-fill syringes, which are made of Cyclic Olefin Copolymer (COC). Over the past 15 years, Schott made significant investments to develop and industrialise COC material for pharmaceutical containers for injectable drugs.

COC is an inert material and the Schott TopPac® syringe system is designed to be compatible with a broad range of drugs. The excellent barrier properties of the Schott TopPac® syringe system allow long term storage of drugs even in small syringe sizes. In addition, Schott TopPac® syringes have a glass-like transparency, and are break resistant and lightweight. Schott TopPac® syringes are available in the range from 1ml to 50ml with cross linked silicone for optimal functionality.

Pharmaceutical companies benefit from the fact that Schott TopPac® syringes are manufactured in clean rooms with a fully automated process starting from injection-moulding to the final packaging in nest and tub. The syringes are sterilised and are ready for aseptic filling operations.

Schott intends to achieve further growth in the field of polymer and glass syringes and also underscores its commitment to offer ideal product solutions to pharmaceutical companies – today and tomorrow.